Correlation Between Mid-cap Value and Biotechnology Ultrasector

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Mid-cap Value and Biotechnology Ultrasector at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mid-cap Value and Biotechnology Ultrasector into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Mid Cap Value Profund and Biotechnology Ultrasector Profund, you can compare the effects of market volatilities on Mid-cap Value and Biotechnology Ultrasector and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mid-cap Value with a short position of Biotechnology Ultrasector. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mid-cap Value and Biotechnology Ultrasector.

Diversification Opportunities for Mid-cap Value and Biotechnology Ultrasector

0.39
  Correlation Coefficient

Weak diversification

The 3 months correlation between Mid-cap and Biotechnology is 0.39. Overlapping area represents the amount of risk that can be diversified away by holding Mid Cap Value Profund and Biotechnology Ultrasector Prof in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Biotechnology Ultrasector and Mid-cap Value is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mid Cap Value Profund are associated (or correlated) with Biotechnology Ultrasector. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Biotechnology Ultrasector has no effect on the direction of Mid-cap Value i.e., Mid-cap Value and Biotechnology Ultrasector go up and down completely randomly.

Pair Corralation between Mid-cap Value and Biotechnology Ultrasector

Assuming the 90 days horizon Mid-cap Value is expected to generate 1.04 times less return on investment than Biotechnology Ultrasector. But when comparing it to its historical volatility, Mid Cap Value Profund is 2.56 times less risky than Biotechnology Ultrasector. It trades about 0.19 of its potential returns per unit of risk. Biotechnology Ultrasector Profund is currently generating about 0.08 of returns per unit of risk over similar time horizon. If you would invest  3,658  in Biotechnology Ultrasector Profund on April 23, 2025 and sell it today you would earn a total of  405.00  from holding Biotechnology Ultrasector Profund or generate 11.07% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Mid Cap Value Profund  vs.  Biotechnology Ultrasector Prof

 Performance 
       Timeline  
Mid Cap Value 

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Mid Cap Value Profund are ranked lower than 15 (%) of all funds and portfolios of funds over the last 90 days. In spite of fairly weak forward indicators, Mid-cap Value may actually be approaching a critical reversion point that can send shares even higher in August 2025.
Biotechnology Ultrasector 

Risk-Adjusted Performance

Modest

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Biotechnology Ultrasector Profund are ranked lower than 6 (%) of all funds and portfolios of funds over the last 90 days. In spite of fairly weak forward indicators, Biotechnology Ultrasector showed solid returns over the last few months and may actually be approaching a breakup point.

Mid-cap Value and Biotechnology Ultrasector Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Mid-cap Value and Biotechnology Ultrasector

The main advantage of trading using opposite Mid-cap Value and Biotechnology Ultrasector positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mid-cap Value position performs unexpectedly, Biotechnology Ultrasector can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biotechnology Ultrasector will offset losses from the drop in Biotechnology Ultrasector's long position.
The idea behind Mid Cap Value Profund and Biotechnology Ultrasector Profund pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Other Complementary Tools

Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum